36-percent increase in pediatric patients treated with proton therapy, new survey shows

Related posts:

1. Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015 CTI BioPharma Corp. and Baxter International's Bioscience business today announced data from PERSIST-1 – a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of myelofibrosis – in a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2015 in Chicago, Ill....
2. Is it in Rochester, Mayo? Or Boston? In the post below, I report on a technical study that reviews the clinical efficacy of proton beam machines. In short, for the most common forms of cancer, there is no appreciable difference in results, but the cost of the proton beam technology greatly exceeds that of technologies generally in use around the world.The exceptions are some of the more difficult forms of cancer, and who can argue with making this modality available to the few people who can benefit from it? Such was clearly the case with 12 year old David Gerfast, who received several weeks of treatment for...
3. Comparative Effectiveness And Cost-Effectiveness Analyses Frequently Agree On Value [Value & Quality] The Patient-Centered Outcomes Research Institute, known as PCORI, was established by Congress as part of the Affordable Care Act (ACA) to promote evidence-based treatment. Provisions of the ACA prohibit the use of a cost-effectiveness analysis threshold and quality-adjusted life-years (QALYs) in PCORI comparative effectiveness studies, which has been understood as a prohibition on support for PCORI’s conducting conventional cost-effectiveness analyses. This constraint complicates evidence-based choices where incremental improvements in outcomes are achieved at increased costs of care. How frequently this limitation inhibits efficient cost containment, also a goal of the ACA, depends on how often more effective treatment is not...
4. Promising research trials find new combination of drugs treat underlying cause of most common form of cystic fibrosis Results from clinical trials show that a new combination of medications can successfully treat the underlying cause of cystic fibrosis for patients 12 and older with two copies of the F508del gene mutation -- the most common form of the life-threatening, genetic disease found in over half of the CF population....
5. Redesigned Geriatric Emergency Care May Have Helped Reduce Admissions Of Older Adults To Intensive Care Units [Improving Care Systems] Charged with transforming geriatric emergency care by applying palliative care principles, a process improvement team at New York City’s Mount Sinai Medical Center developed the GEDI WISE (Geriatric Emergency Department Innovations in Care through Workforce, Informatics, and Structural Enhancements) model. The model introduced workforce enhancements for emergency department (ED) and adjunct staff, including role redefinition, retraining, and education in palliative care principles. Existing ED triage nurses screened patients ages sixty-five and older to identify those at high risk of ED revisit and hospital readmission. Once fully trained, these nurses screened all but 6 percent of ED visitors meeting the screening...